Alnylam, Max Planck Say University of Utah Fails to Show How Researcher Collaborated on Tuschl-II | GenomeWeb

By Doug Macron

Alnylam Pharmaceuticals and the other co-defendants embroiled in an RNAi-related intellectual property lawsuit have requested that the case be dismissed, alleging that the plaintiff, the University of Utah, has not demonstrated how one of its researchers participated in developing the technology covered by the patents at issue.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.